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Abstract
Purpose Survival after liver transplantation (LTX) has
decreased in Germany since the implementation of
Model for end-stage liver disease (MELD)-based liver
allocation. Primary sclerosing cholangitis (PSC) is
known for its otherwise excellent outcome after LTX.
The influence of MELD-based liver allocation and sub-
sequent allocation policy alterations on the outcome of
LTX for PSC is analyzed.
Methods This is a retrospective observational study including
126 consecutive patients treated with LTX for PSC between
January 1, 1999 and August 31, 2012. The PSC cohort was
further compared to all other indications for LTX in the study
period (n=1420) with a mean follow-up of 7.9 years (SD 3.2).
Multivariate risk-adjusted analyses were performed. Alter-
ations of allocation policy have been taken into account
systematically.
Results Transplant recipients suffering from PSC are sig-
nificantly younger (p<0.001), can be discharged earlier
(p=0.018), and have lower 3-month mortality than patients
with other indications (p=0.044). The observed time on the
waiting list is significantly longer for patients with PSC
(p<0.001), and there is a trend toward lower match MELD
points in the PSC cohort (p=0.052). No improvement in
means of short-term mortality could be shown in relation to
alterations of allocation policy within the MELD era (p=
0.375). Survival rates of the pre-MELD era did not differ
significantly from those of the MELD era (p=0.097) in
multivariate risk-adjusted analysis. Patients in the MELD
era suffered pre-transplant significantly more frequently
from dominant bile duct stenosis (p=0.071, p=0.059, p=
0.048, respectively; chi2).
Conclusions Progress is stagnating in LTX for PSC. Current
liver allocation for PSC patients should be reconsidered.
Keywords MELD-based allocation . Cholangiocarcinoma .
Outcome . Survival . Autoimmune liver disease .Multivariate
analysis
Introduction
Primary sclerosing cholangitis (PSC) is a chronic inflamma-
tory disease affecting both the small and large intrahepatic and
extrahepatic bile ducts leading to biliary ectasis, strictures,
and, consequently, cholestasis and liver cirrhosis [1]. Liver
transplantation (LTX) represents the only curative treatment
option for PSC. Patient’s survival after LTX reaches 82, 77,
and 75 % at 1, 3, and 5 years, respectively [2, 3]. There is an
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increased risk of developing cholangiocarcinoma (CC) as well
as the impact of concomitant inflammatory bowel disease
(IBD) which appears to be present in 70–80 % of all PSC
patients and an additionally increased risk of colorectal cancer
[1, 4, 5].
Since the implementation of the Model for End-Stage
Liver Disease (MELD) for donor liver allocation in
Germany in January 2007, it has been suspected that
patients with PSC may be disadvantaged by the sickest-
first principle of MELD-based liver allocation. This
notion is justified by the fact that PSC patients typically
experience a comparatively stable disease over
prolonged periods of time until they may decompensate
and/or develop CC and thus may no longer be trans-
plantable with reasonable outcome. MELD-based alloca-
tion is based on abnormal coagulation, impaired renal
function, and high levels of serum bilirubin. In fact,
only high bilirubin levels are constantly observed in
PSC patients and were suggested to represent a signif-
icant predictive risk factor [6]. Therefore, conditions for
the award of exception points were defined [7]. These
conditions include ≥2 episodes of culture-proven bacter-
emia within the last 6 months or septic complications of
cholangitis without a biliary tube or stent in situ and
were introduced in active allocation on June 27, 2008
[8]. However, only a small proportion of PSC patients
fulfill the qualifications for exception points, and the
remaining patients are still at risk to develop CC while
waiting years for LTX until they gain a sufficiently high
MELD score due to increased liver failure. Therefore,
allocation policies for patients suffering from PSC have
been adapted subsequently on March 13, 2012 (e.g.,
assignment of 22 MELD points at day of listing) [9].
It can be assumed that current donor liver allocation for
PSC patients may preclude optimal outcomes after LTX. The
introduction of MELD-based liver allocation in Germany in
December 2006 has decreased waiting list mortality from 20
to 10 % but, at the same time, has reduced posttransplant 1-
year survival from almost 90 to below 80 % [10, 11]. Follow-
ing MELD introduction, the regular allocation threshold has
increased in Germany from a MELD of initially 25 to now 34
points. At the same time, the quality of donor organs has seen
a continuous deterioration in most Eurotransplant countries
over the last 10–15 years [11].
The current study investigates the outcome of LTX for PSC
in the pre-MELD and MELD era, taking subsequent changes
of allocation policy into account and systematically compares
PSC patients with other indications for LTX. The PSC patient
cohort is further analyzed in depth regarding differences be-
tween the pre-MELD and MELD era. It is intended to analyze
whether the different allocation policies lead to an intended
improvement of outcome or whether there was a stagnation of
clinical scientific progress.
Patients and methods
This is a retrospective observational analysis of 126 consecu-
tive patients who received an LTX for PSC at Hannover
Medical School between January 1, 1999 and August 31,
2012. A total of 1420 consecutive LTXs for other indications
than PSC in the same time frame served as a control cohort for
statistical comparison. Living donor transplantations were
excluded because organ allocation was not based on the
MELD score (n=118; 7.6 %). The required minimum
follow-up was 3 months. Mean follow-up was 7.9 years (SD
3.2). Patient’s data of the PSC cohort included age, sex,
biochemical parameters (creatinine, bilirubin, international
normalized ratio (INR), cholinesterase, (CHE), aspartate ami-
notransferase (AST), and alanine aminotransferase (ALT)) at
date of listing and LTX and the absence or presence of IBD
inclusive the onset of colorectal cancer. For those patients in
the early years of this millennium where INR was not routine-
ly determined, the value was estimated based on the prothrom-
bin time. The laboratory MELD score (lab MELD) was cal-
culated for all patients as described previously [12]. Addition-
ally, the proportion of patients after implementation of the
MELD score was classified into those who fulfilled the qual-
ification for exception points and those who did not, according
to policy changes on the June 27, 2008 and March 13, 2012
[8, 9, 12], resulting in the match MELD as described by
Eurotransplant, which was used for actual organ allocation
[12]. Furthermore, the influence of typical PSC complications
(e.g., dominant bile duct stenosis and hepatobiliary (HB)
surgery prior to transplantation or the onset of CC) on the
outcome after LTX was analyzed. Donor characteristics like
age, sex, graft type (split versus full organ), and cold ischemia
time (CIT) were taken into account.
Study endpoints
The primary study endpoints were 30-day mortality, 3-month
mortality, and long-term survival after LTX. Secondary end-
points were the onset of surgical complications classified as
proposed by Dindo et al. [13].
Statistical analysis
Categorical variables were compared using the Pearson’s chi2
test (chi2); the Mann-Whitney U test (MWU) was used to
compare continuous data. Means were compared with the
Student’s two-sided t test. The study endpoints, 3-month
mortality, 30-day mortality, and onset of complications were
analyzed with binary logistic regression analysis. Survival
analysis was performed with Kaplan-Meier estimation and
Cox regression analysis. Relevant risk factors for survival
were identified with univariate Cox regression. The alpha
level in univariate Cox regression was set at p=0.1 to ensure
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that also variables with comparatively small impact were
considered for risk-adjusted analysis. Multivariate, risk-
adjusted Cox proportional hazard models were then created
including all significant variables from univariate analysis to
identify relevant, independent risk factors for survival after
LTX. For all other statistical tests, a p value <0.05 was defined
as significant. Calculations were performed using SPSS 21.0
(IBM, Somers, NY, USA).
Results
Patient characteristics
Eighty-five (31 female=36%; 54 male=64%) of 959 patients
(8.8 %) were transplanted for PSC in the pre-MELD era
(January 1, 1999 to December 31, 2006); 41 (14 females=
34%; 27males=66%) of 487 patients (7.2%) received a liver
allograft due to PSC after the implementation ofMELD-based
allocation (p=0.236; chi2). The percentage of pediatric pa-
tients (defined as <18 years) was significantly higher in the
non-PSC cohort (<0.001; chi2). The PSC cohort had a median
age of 40 years (range 3–66 years). Seventy-four of the 126
PSC patients (58.7 %) suffered from IBD prior to transplan-
tation; 13 patients (10.3 %) were diagnosed with colon cancer
prior to LTX. A split graft was transplanted in 20.6 % of all
PSC cases (n=26).
Comparison of PSC patients with other indications leading
to LTX in the MELD era
Table 1 summarizes the results of the statistical comparison of
patient characteristics and outcome data of transplant
recipients with versus without PSC in the MELD era. Trans-
plant recipients suffering from PSC are significantly younger
(p<0.001), can be discharged earlier (p=0.018), and have
lower 3-month mortality than patients with other indications
(p=0.044). The observed time on the waiting list is signifi-
cantly longer for patients with PSC (p<0.001), and there is a
trend toward lower match MELD points in the PSC cohort,
although this analysis does not reach statistical significance
(p=0.052). Recipients transplanted for PSC have significantly
longer survival than all other indications for LTX (p=0.039;
log-rank) (see Fig. 1).
Patient survival
As summarized in Table 2, the multivariate Cox regression
model for analysis of differing survival outcome in the pre-
MELD versus theMELD era was risk-adjusted for CC prior to
LTX, histologically proven CC in the explanted recipient liver,
CC after LTX, first part of the MELD era (as defined above),
and basiliximab as immunosuppressive induction therapy af-
ter LTX. All other investigated variables did not reach signif-
icance in univariate Cox regression analysis (p<0.1). The
multivariate Cox regression analysis revealed CC after LTX
as the only independent risk factor for mortality (p<0.001; HR
43.841; 95 % confidence interval (CI) 9.483–202.678). Nei-
ther being transplanted in the MELD era (p=0.097) nor being
one of the MELD sub-eras as defined by changes in allocation
policy leads to an independently increased or decreased mor-
tality risk in multivariate analysis (p=0.055). Three-month
mortality as well as 30-day mortality did not significantly
differ between the pre-MELD and the MELD era (both p=
0.202, multivariate binary logistic regression analysis). No
improvement in means of short-term mortality could be
shown in relation to alterations of allocation policy within
Table 1 The results of the comparison of patient characteristics and outcome data of transplant recipients with versus without PSC in the MELD era
PSC cohort (n=126) Non-PSC cohort (n=1420) p value
Age at transplant (mean; SD) 43 (11) 50 (13) <0.001a
Length of hospital stay (mean; SD) 35 (21) 53 (49) 0.018a
Operative duration (min) (mean; SD) 226 (51) 222 (71) 0.713a
CIT (min) (mean; SD) 616 (152) 573 (176) 0.095a
Survival (years) (mean; SD) 1.7 (0.9) 1.5 (1.2) 0.397a
Days on the waiting list (mean; SD) 854 (897) 294 (441) <0.001a
Lab MELD (mean; SD) 19 (10) 21 (11) 0.387a
Match MELD (mean; SD) 22 (10) 26 (10) 0.052a
Necessity of postoperative revision 19 (45.2 %) 233 (57.7 %) 0.122b
3-month mortality 2 (4.9 %) 67 (16.9 %) 0.044b
30-day mortality 2 (4.9 %) 48 (11.8 %) 0.168b
PSC primary sclerosing cholangitis, SD standard deviation, CIT cold ischemic time
a Student’s t test
b Pearson’s chi2 test
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the MELD era (p=0.375; multivariate binary logistic regres-
sion analysis).
Hepatic artery thrombosis and graft loss
Nine of 126 transplant recipients of the PSC cohort (7.4 %)
developed a hepatic artery thrombosis (HAT) during follow-
up, whereas HAT was observed in 59 non-PSC patients
(4.5 %) in the same follow-up time (p=0.120; chi2). Occur-
rence of HAT after LTX was a significant risk factor for graft
loss (p<0.001; HR 5.104; 95 % CI 3.867–6.738; Cox
regression).
Complications after LTX for PSC
The proportion of postoperative complications was compara-
ble in both groups and displayed no significant differences
between patients who were transplanted in the MELD era as
compared to those patients transplanted in the pre-MELD era
(p=0.233; MWU; see Table 3). This result was confirmed by
multivariate binary logistic regression analysis for the end-
point “postoperative complication yes/no,” which remained
insignificant (p=0.760).
Biochemical parameters and MELD scores
Biochemical parameters at the time of listing and at the day of
LTX are summarized in Table 4. At the time of listing, patients
in the MELD era have significantly higher lab MELD scores
(p=0.002), higher levels of bilirubin (p=0.010), higher INR
values (0.003), and higher AST levels (p=0.008). At the day
of LTX, significantly increased lab MELD scores (p<0.001),
higher bilirubin values (p<0.001), increased INR levels (p=
0.006), as well as lower CHE levels (0.031) were observed in
the MELD era.
Preoperative PSC-related features
Table 5 summarizes the clinical characteristics of investigated
PSC patients. Patients in the MELD era suffered pre-
transplantation more frequently from typical PSC-related
complications, namely, recurrent cholangitis, dominant bile
duct stenosis, and dysplasia in brush cytology. However, only
the development of a dominant bile duct stenosis was signif-
icantly more frequent among patients in the MELD era (39
versus 23.5 %; p=0.048; chi2). Six patients developed a re-
manifestation of PSC during follow-up (4.8 %). Four percent
of the PSC cohort (n=5) were diagnosed with CC during
follow-up. The presence of concomitant IBD was equally
distributed between both groups. An active form or compli-
cated course of the disease was more frequent among patients
in the pre-MELD era without reaching statistical significance
(p=0.317).
p=0.039; Log-Rank
Fig. 1 Survival of patients with PSC versus patients with other indica-
tions leading to LTX
Table 2 The results of the analysis of long-term survival of patients transplanted for PSC, which were significant in univariate and multivariate Cox
regression analyses
Univariate Cox regression Multivariate Cox regression
p value HR (95 % CI) p value HR (95 % CI)
MELD era yes/no 0.016 4.631 (1.357–15.803) 0.097 n.a.
CC prior to transplant 0.030 5.514 (1.481–20.526) 0.605 n.a.
CC in the recipient liver histology <0.001 18.069 (5.300–61.601) 0.817 n.a.
CC after LTX <0.001 43.841 (9.483–202.678) <0.001 43.841 (9.483–202.678)
Part 1 MELD era 0.021 4.752 (1.260–17.928) 0.055 n.a.
Basiliximab induction 0.081 n.a. 0.345 n.a.
Part 1 MELD era: from introduction of MELD-based allocation (January 1, 2007) until first allocation change for PSC patients (June 27, 2008)
MELDModel for End-Stage Liver Disease,HR hazard ratio, 95 % CI 95 % confidence interval, CC cholangiocarcinoma, LTX liver transplantation, n.a.
not available
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Analysis of PSC patients in the MELD era
The mean time on the waiting list increased since intro-
duction of MELD-based allocation from 1.6 to 2.3 years
without reaching statistical significance (p=0.068; t test).
Twenty-six of 41 patients (63 %) in the MELD era ful-
filled the criteria for exception points. Patients within the
MELD era who gained exception points during their
waiting time had a significantly longer overall waiting
time (mean 2.67 (n=26) versus 1.64 years (n=15), p=
0.045; MWU). Nevertheless, waiting time from the first
award of exception points until transplantation was
significantly reduced to a mean waiting period of 191 days
(median 110.5 days, range 0–487 days) as compared to
cases without any exceptions points until LTX (mean
567 days, range 4–2,614 days) (p=0.021, MWU). Cumu-
lative survival among patients with or without exception
points did not differ significantly (p=0.634; log-rank).
Postoperative PCS-related features
We further analyzed the course of PSC-associated co-
morbidities after LTX. In the pre-MELD versus the MELD
era, there was no statistical difference concerning the occur-
rence of CC, recurrent cholangitis, IBD relapse or active
course of disease, the occurrence of colorectal cancer, the
development of posttransplant lymphoproliferative disease
(PTLD), or more than one treatable episode of rejection after
LTX observed. Results are summarized in Table 5.
Discussion
Against the background of currently diminishing donor num-
bers and a situation in the German transplant community
which is further sharpened by several transplant scandals
about manipulating liver transplant waiting lists, the current
MELD-based donor liver allocation is widely discussed [14].
It is evident that the public expects trustworthy, transparent,
and ethical donor organ allocation rules which enable optimal
Table 3 Surgical complications after LTX for PSC before and after
implementation of MELD-based allocation (p=0.233; MWU)
Clavien-Dindo score Pre-MELD MELD Total
I 8 0 8
I–II 38 20 58
II 6 3 9
IIIa 5 2 7
IIIb 8 6 14
Iva 1 2 3
IVa 7 3 10
Ivb 1 1 2
IVb 9 2 11
V 2 1 3
Categorized with the Clavien-Dindo score
Table 4 Patient characteristics and biochemical parameters at time of listing and at day of LTX
Pre-MELD era (n=85) MELD era (n=41) p value
Age at the time of listing; median (range) 36 (2–62) 40 (15–61) 0.140a
Sex (females/males) 31 (36 %)/54 (64 %) 14 (34 %)/27 (66 %) 0.799b
Lab MELD at day of listing; mean (SD) 10 (4) 13 (7) 0.002c
Bilirubin (μmol/l) at day of listing; mean (SD) 50.7 (83.2) 107.2 (156.7) 0.010c
Creatinine (μmol/l) at day of listing; mean (SD) 61.5 (13.9) 65.9 (23.0) 0.262c
INR at day of listing; mean (SD) 1.1 (0.2) 1.2 (0.3) 0.003c
CHE (kU/l) at day of listing; mean (SD) 4.6 (2.1) 4.4 (2.0) 0.520c
AST (U/l) at day of listing; mean (SD) 62.1 (61.8) 98.6 (72.5) 0.008c
ALT (U/l) at day of listing; mean (SD) 76.9 (75.4) 94.4 (75.3) 0.231c
Lab MELD score at day of LTX; mean (SD) 11 (6) 18 (7) <0.001c
Bilirubin (μmol/l) at day of LTX; mean (SD) 69.9 (119.6) 209.5 (234.2) <0.001c
Creatinine (μmol/l) at day of LTX; mean (SD) 62.7 (24.1) 73.4 (36.3) 0.095c
INR at day of LTX; mean (SD) 1.2 (0.4) 1.4 (0.5) 0.006c
CHE (kU/l) at day of LTX; mean (SD) 4.7 (2.4) 3.7 (2.2) 0.031c
AST (U/l) at day of LTX; mean (SD) 112.9 (294.7) 117.3 (80.6) 0.900c
ALT (U/l) at day of LTX; mean (SD) 93.2 (101.2) 95.5 (67.8) 0.882c
aMann-Whitney U test
b Pearson’s chi2 test
c Student’s t test
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graft utilization and avoid donor organ waste in cases with
foreseeable futile transplantation. After the introduction of
MELD-based liver allocation, an increase in short-term mor-
tality and sub-par survival rates after LTX has been observed
[10, 15]. This observation casts serious doubts on the optimal
utilization of donor livers with the current donor organ allo-
cation policy. This in turn raises questions in relation to the
ethical justifiability of the system as a whole and of a signif-
icant and indefensible systemic disadvantage to certain patient
groups (e.g., PSC). Issues with distributive justice in MELD-
based allocation systems have already been the subject of
criticism [16]. Especially PSC patients, who have an other-
wise excellent outcome as compared to other indications
leading to LTX, could be disadvantaged by the current liver
allocation policies [2, 17–20]. The survival rates for PSC
patients after LTX are de facto excellent and exceed 75 %
after 5 years in the USA and Scandinavia [2, 3, 21, 22]. The
presented data supports this notion (see Fig. 1). Moreover,
LTX is the only available curative therapy for PSC [18, 19].
It is undisputed that the short-term and long-term progno-
ses after LTX are largely dependent on the nature of the
underlying liver disease, the overall morbidity and condition
of the recipient, and donor liver quality, which is notoriously
difficult to define [23–26]. This insight has lead to several so-
called “standard exceptions” in MELD-based liver allocation,
e.g., for cases with hepatocellular carcinoma or PSC [12].
Currently, about 60 % of all donor livers are allocated in
Germany according to the original MELD score (so-called
lab MELD) while the remainder are allocated due to standard
exceptions, “non-standard exceptions,” and “rescue alloca-
tions” [11, 27]. In conclusion, this situation provided further
motivation to analyze the current outcomes in LTX for PSC
patients since the systematic introduction of MELD-based
liver allocation in Germany.
Interestingly, patients who gained exception points during
their waiting time had a longer overall waiting time for LTX.
However, when analyzing the time from the first award of
exception points until transplantation, mean waiting time is
significantly shorter as compared to patients without any
exception points during their waiting time. These findings
confirm the assumption that listing with exception points
reduces waiting time. We believe that posttransplant mortality
and waiting time could be reduced, and finally, survival after
LTX for PSC patients could be improved with the use of a
more adequate donor liver allocation policy.
Our data indicates that the cumulative survival of PSC
patients who underwent LTX has not declined significantly
after the implementation of MELD-based allocation. This is
an important difference compared to previously published
data on outcomes after LTX for all indications in Germany
in the pre-MELD versus the MELD era [10, 11, 15]. As
expected, in the present cohort of PSC patients, mean lab
MELD values were higher in the MELD era prior to LTX.
This observation was previously shown for all indications for
LTX in Germany [10]. This series shows, in line with previous
publications, that higher lab MELD scores are associated with
a deteriorated biochemical profile, including poor liver and
kidney functions and poor coagulation [10]. After the intro-
duction of MELD-based allocation in the present series,
waiting time increased without reaching statistical signifi-
cance. Patients who were transplanted in the MELD era had
to wait longer (mean waiting time 2.3 years) for LTX as
Table 5 The frequencies of PSC-
related features as well as preop-
erative and postoperative compli-
cations for all patients who
underwent LTX for PSC
Pre-MELD (n=85) MELD (n=41) p value (chi2)
Recurent cholangitis prior to LTX 20 (23.5 %) 16 (39 %) 0.071
Dominant bile duct stenosis 30 (35.3 %) 24 (58.5 %) 0.048
Dysplasia in brush cytology 5 (5.9 %) 7 (17.1 %) 0.059
CC prior to LTX 7 (8.2 %) 2 (4.9 %) 0.493
HB surgery prior to LTX 7 (8 %) 6 (14.6 %) 0.269
IBD prior to LTX 49 (57.6 %) 25 (61 %) 0.219
Active IBD prior to LTX 20 (40.8 %) 7 (28 %) 0.317
Colorectal cancer prior to LTX 9 (10.6 %) 4 (9.8 %) 0.954
Cirrhosis in explanted liver 60 (70.6 %) 30 (73.2 %) 0.522
CC in explanted liver 6 (7.1 %) 3 (7.3 %) 0.958
CC after LTX 5 (5.9 %) 1 (2.4 %) 0.395
Recurrent cholangitis after LTX 20(23.5 %) 7 (17.1 %) 0.408
Re-PSC after LTX 5 (6.4 %) 1 (2.6 %) 0.374
IBD relapse after LTX 3 (3.5 %) 0 (0 %) 0.223
Colorectal cancer after LTX 3 (3.5 %) 0 (0 %) 0.223
PTLD after LTX 1 (1.2 %) 0 (0 %) 0.486
Rejection after LTX 24 (28.2 %) 7 (17.1 %) 0.173
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compared to previously presented data from Scandinavia and
the USA (mean waiting time of 1 month and 1 year, respec-
tively) [18, 21]. Noteworthy, in contrast to Germany and the
USA, liver allocation in Scandinavia is not MELD-based [18].
The biggest concern for PSC patients is the development of
disease-typical complications [1]. This includes primary dom-
inant bile duct stenosis and, consequently, an increased risk
for cholangitis, cholangiosepsis, and/or CC. Moreover, every
dominant bile duct stenosis could mimic CC, whereas the
differentiation between benign strictures and malignant steno-
sis might be difficult [28]. There are no distinct risk factors for
the development of CC in PS; however, increased waiting
time for LTX is assumed to increase the risk for CC. Although
we observed a higher incidence of dominant bile duct stenosis
accompanied with a trend toward higher frequency of cell
dysplasia in biliary brush cytology among patients in the
MELD era, there was no statistical difference in the incidence
of CC before LTX or incidentally in the explanted livers as
compared to the pre-MELD era. Thus, increased waiting time
in the MELD era did not result in an increased incidence of
CC (see Table 5). The reason for the higher frequency of
dominant bile duct stenosis in the MELD era remains unclear.
One speculation might be more thorough and possibly more
frequent endoscopic examinations in the care of PSC patients
within the last years.
Hepatobiliary surgery prior to LTX is known to affect the
outcome negatively even after exclusion of patients with
malignancy [3, 29, 30]. Although we observed a higher inci-
dence within the MELD era, hepatobiliary surgery prior to
LTX did not influence the outcome of LTX significantly in our
cohort. Consequently, we cannot confirm that hepatobiliary
surgery in PSC patients should be avoided due to a potential
risk for poor survival after LTX as suggested before [3].
Concomitant IBD represents a relevant risk factor for re-
duced survival among PSC patients after LTX as well [30].
Neither the incidence of concomitant IBD nor the onset of
colorectal cancer was represented differently in the pre-
MELD versus the MELD era. However, in contrast to previ-
ous studies, we did not further differentiate the type of IBD [3,
30].
The rate of postoperative complications and re-transplants
did not differ significantly between the pre-MELD andMELD
era. It is well known that arterial thrombosis is not only the
main indication for re-transplantation; it was also reported to
occur more frequently in PSC patients [3, 23, 31]. In our
cohort, we also identified arterial thrombosis as a primary
reason leading to re-transplantation, followed by primary
non-function.
PSC patients are known to suffer more frequently from one
or more episodes of rejection after LTX as compared to
patients who underwent LTX due to other liver diseases
[32]. We observed in our cohort a higher frequency of rejec-
tions among patients in the pre-MELD era as compared to the
MELD era without reaching statistical significance. The high
frequency of rejections is in line with data from the literature
reporting of 20–40 % of patients who will suffer from at least
one episode of rejection [32, 33]. One or more episodes of
rejection early after LTX are suspected to be associated with
PSC recurrence [32]. Despite the long observation period, we
only observed a low frequency of disease recurrence (6.4 %)
compared to the data presented in previous studies (5.7–
59.1 %) [32]. The difference in PSC recurrence before versus
after implementation of MELD-based allocation did not reach
statistical significance.
In a recently published analysis of the incidence and long-
term risk of de novo malignancy in the liver transplant cohort
from Hannover covering a total of 2,000 patients after LTX
with a total of 14,490 person years of follow-up including 180
patients transplanted for PSC, we could not find a significantly
increased risk for PTLD in these patients as compared to an
age-matched normal population or as compared to other indi-
cations leading to LTX, but we did find an increased risk for
colorectal carcinoma in PSC patients after transplantation
[34]. It is therefore unsurprising that the incidence of PTLD
after LTX was very low in this study.
One limitation of our single-center study is its retrospective
character and potential center bias. Further, the number of
patients is relatively small with a rather short follow-up time.
Finally, we did not analyze patients who were removed from
the waiting list due to severe complications such as advanced
CC or death caused by liver failure. The influence of de-
creased donor organ quality over time in the present series is
largely speculative, although an increased donor age after
implementation of MELD-based allocation has been ob-
served. However, it has been shown that current donor organ
quality scores (DRI, ECD score, D-MELD score, ET-DRI) did
not influence outcome after LTX in our center in the MELD
era [24, 35].
Despite the fact that the criteria which must be fulfilled in
order to gain exception points do not represent the whole
spectrum of potential complications with prognostic relevance
in PSC patients, the alterations of allocation policy during the
study period seemed to be able to prevent further disadvan-
tages of PSC patients in means of comparable outcomes with
other indications leading to LTX. Nevertheless, only a deteri-
oration of results could be prevented.
The data of this study underlines the conclusion that before
and after the implementation ofMELD-based allocation, there
is no progress and rather stagnation in outcome after LTX for
PSC, pointing to a lack of medical progress for these patients
which is even more pronounced for patients with other indi-
cations for LTX who experience worse outcomes since the
introduction of MELD-based allocation in Germany. These
aspects warrant, at least in our view, the conclusion that liver
allocation for PSC patients should be reconsidered. The de-
lineation of what type of modifications would improve the
Langenbecks Arch Surg (2014) 399:1021–1029 1027
long-term prognosis/outcome of PSC patients after transplan-
tation needs to take into account the problem of ubiquitous
donor organ shortage and the mechanisms of a justifiable
distribution of this very rare resource, which needs to take
into account all other indications for LTX and the fact that
donation rates are currently significantly decreasing in Ger-
many since 2012. The current study was not designed and able
to provide a comprehensive solution to improve the current
organ allocation dilemma that would have to take into account
also further aspects such as urgency and utility of LTX.
However, the current study does show the relevance of PSC-
specific complications as well as the influence of recent alter-
ations of allocation rules on outcome after transplantation for
PSC. Surveillance of the influence of organ allocation rule
changes on outcome for specific patient groups is necessary
and provides valuable information for the ongoing and current
debate on allocation rules.
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